How Has Recreational Legalization Affected MMJ Patients?
Jeremy Martin
January 5th, 2017
Policy, Top News
For Bill Fredericks the pain began slowly. A sports injury to his toe that wouldn’t quite heal began affecting his entire foot and then his knee. Over time he would deal with chronic lower back pain, preventing him from exercising and distracting him at work. An employee in Seattle’s booming construction industry, Fredericks needed complete mobility to do his job.
“I was fitted with orthopedics which actually caused more pain, Fredericks said. “I took lots of over the counter pain meds like Tylenol.”
Than in 2013 he applied for a medical marijuana ‘green card.’
“I wanted access to tinctures and things like that, that would help me sleep better and manage the pain. Balms, it turned out were a really pleasant surprise,” Fredericks said.
So too were the prices. It had been eighteen years since Initiative 692 legalized medical cannabis in Washington State and the prices, according to Frederick, $8 grams, $20 single ounce vials of tincture were indicating a healthy, mature industry.
However, for Fredericks, and all of Washington’s medical marijuana patients, things would change dramatically the following year when the state’s recreational cannabis industry launched. In essence, Initiative 502 merged the structured, well established medical industry with with a recreational industry, that in comparison seemed like the wild, wild west.
Those $8 grams would quickly become $20 or even $25, tinctures were harder to come by, and balms were difficult to find in recreational stores.
This all begs the question. Is Washington a model for the recreational transition or does it come off as a cautionary tale for states like California that voted this past fall to legalize recreational cannabis?
Most likely the latter. As Russ Belville, cannabis author and host of The Russ Belville Show on cannabisradio.com explains “California learned from that lesson. Their legislature rushed to get statewide marijuana regulations in place before what they knew would be an inevitably successful push for legalization in 2016.”
That push was Prop 64, which legalizes the possession, consumption, and growth of ‘small amounts’ of marijuana in the state of California.
What it doesn’t do is abolish the state’s medical industry, which currently brings in nearly $5 Million dollars annually and serves over 750,000 people.
Taking that into account, and the potential for early recreational prices to spike, state lawmakers are planning to abolish existing use taxes on medical marijuana while levying a 15% tax on all recreational sales.
That’s in line with Colorado, which currently has the lowest tax rate of all states currently offering legal recreational marijuana. Though, by the time the first legal gram is sold in the Golden State, Colorado will have lowered its rate to 8%.
It’s very possible that California’s recreational and medical industries will function, at least financially in a similar way to those in Colorado. According to taxfoundation.org, sales of recreational cannabis in the Rocky Mountain state has grown steadily over the past year, with monthly sales near $60 million. All the while the medical industry has continued to function at a high level, though its sales have leveled off, averaging around $30 million per month.
In Colorado, as sales rise, prices drop, With grams in the Denver metro area are currently around $10. Outside the metro that same cannabis costs around $15. That being said, we’re looking at an average drop of around 7% statewide since the fall of 2015.
Despite an initial 37% recreational tax, Washington too has noticed a similar trend in both pricing and revenue with average retail sales around $62 million monthly. Gram prices, though currently at an average of $13 and dropping are still well above what some medical patients had been accustomed to paying.
Though Washington residents have dealt with some inconsistencies and changes in their cannabis purchasing routines, if Colorado’s example is to be followed, and it appears that it is, California’s medical and recreational buyers should feel a little more secure in their abilities to procure affordable, high quality marijuana in the coming years.
If you found this article informative and would like to stay up to date on other cannabis related topics, please sign up for our free newsletter by using the form to the right.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Jeremy Martin
Jeremy Martin is a Seattle-based writer reporting on coffee, craft beer, music, college sports, cannabis and business for a variety of publications. A competitive disc golfer and avid sandwich maker, he graduated from Western Michigan University in 2009. He and his wife are expecting their first child in July.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
BDS Analytics aims to drive the cannabis sector to thrive with well-informed decisions based on factual data. By capturing millions of transactions from dispensary point-of-sale systems we provide actionable insights based on accurate information enabling dispensaries, brands, and growers to sustain their success. Their vision is to be your indispensable source for cannabis industry data […]
Zenabis owns 660,000 square feet of high quality indoor facility space, as well as 2.1 million square feet of greenhouse space that will be dedicated to cannabis production once fully built-out.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
